Table 2.

Anti-HER2 ADCs in clinical trials or on the market.

ADC Name	Indication	Trial ID	Phase	Reference
Fam-trastuzumab deruxtecan-nxki	Metastatic breast cancer	-	Approved	[93,94,95]
Ado-trastuzumab emtansine	Metastatic breast cancer	-	Approved	[19,96]
Disitamab vedotin	Metastatic gastric cancer	NCT04714190	Phase III/Approved in China	[97,98,99,100]
Vic-trastuzumab duocarmazine	Metastatic breast cancer	NCT03262935	FDA accepted BLA 1/Phase III	[29,101]
ZRC-3256	Metastatic breast cancer	CTRI/2018/07/014881	Phase III	[102]
TAA013	Metastatic breast cancer	CTR20200806	Phase III	[103]
ARX788	Metastatic breast cancer/gastric cancer	CTR20201708	Phase II/III	[104]
MRG002	Metastatic breast cancer	NCT04492488	Phase II	[105]
DP303c	Gastric Cancer	NCT04146610	Phase II	[106]
BDC-1001	Metastatic breast cancer/gastric cancer	NCT04278144	Phase I/II	[107]
A166	Metastatic breast cancer	NCT03602079	Phase I/II	[108,109]
SBT6050	Advanced solid tumors	NCT05091528	Phase I/II	[110]
SHR-A1811	Advanced solid tumors	NCT04446260	Phase I/II
SHR-A1201	Metastatic breast cancer	CTR20191558	Phase I/II
MT-5111	Advanced solid tumors	NCT04029922	Phase I	[111]
ALT-P7	Metastatic breast cancer	NCT03281824	Phase I	[112]
ZW49	Metastatic breast cancer	NCT03821233	Phase I	[113]
FS-1502	Breast Cancer	NCT03944499	Phase I
BI-CON-02	Metastatic breast cancer	NCT03062007	Phase I
DX126-262	Breast/gastric cancer	CTR20191224	Phase I
HS630	Breast Cancer	CTR20181755	Phase I
B003	Metastatic breast cancer	NCT03953833	Phase I
GQ1001	Advanced solid tumors	NCT04450732	Phase I

¹ accepted for review a biologics license application (BLA).